Andrew S. Fein Stock Analyst Profile - HC Wainwright & Co. Research Coverage - Stocknear

Andrew S. Fein

Stock Analyst at HC Wainwright & Co.

(5)
# 351
Out of 5,506 analysts
18
Total ratings
Success rate
Average return

15 Stocks

Name Action PT Current % Upside Ratings Updated
PVLA Palvella Therapeutic...
Maintains: Strong Buy
75 95
65.78 44.42% 2 Sep 25, 2025
ETNB 89bio
Downgrades: Neutral
15
14.85 -2.36% 2 Sep 19, 2025
KYMR Kymera Therapeutics
Maintains: Strong Buy
60 70
57.9 20.9% 1 Sep 18, 2025
TERN Terns Pharma
Assumes: Neutral
8
8.23 -9.6% 1 Sep 4, 2025
MTVA MetaVia
Assumes: Buy
12
1.03 1065.05% 1 Sep 4, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Buy
500
443.01 12.86% 1 Sep 4, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Buy
60
22.56 165.96% 1 Sep 4, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Buy
72
46.1 56.18% 1 Sep 4, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
22 22
7.15 207.69% 1 Sep 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
5 8
3.49 129.23% 2 Sep 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
120 240
157.16 52.71% 1 Aug 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
24 18
9.61 87.3% 1 Aug 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
36 25
7.95 214.47% 1 Aug 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
14 14
9.92 41.13% 1 Aug 5, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
550 478
403.12 18.58% 1 Aug 5, 2025